Evidence map›Paper›PMID 37120522›Full record

ArticleJournal of neurodevelopmental disorders2023

Rare recurrent copy number variations in metabotropic glutamate receptor interacting genes in children with neurodevelopmental disorders.

Joseph T Glessner, Munir E Khan, Xiao Chang, Yichuan Liu, F George Otieno, Maria Lemma, Isabella Slaby, Heather Hain, Frank Mentch, Jin Li and 5 more

4 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Journal of neurodevelopmental disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02286817 phase1completednot on this map

Phase I Single Dose, Open-label, Pharmacokinetic Study Followed by Single-blind, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Plasma Concentration Profiles, and Targeted Efficacy of NFC-1 in Adolescents (12-17 Years of Age) With Attention-Deficit Hyperactivity Disorder and Genetic Disruption Impacting Metabotropic Glutamate Receptor Genes (NFC1-GREAT)

TypeinterventionalSponsorAevi Genomic Medicine, LLC, a Cerecor companyRan2015 to 2016Enrolled30ConditionsAttention-deficit Hyperactivity Disorder (ADHD)ArmsNFC-1
NCT02777931 phase2 / phase3completednot on this map

A Multicenter, 6-week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17) With Genetic Disorders Impacting Metabotropic Glutamate Receptors and ADHD

TypeinterventionalSponsorAevi Genomic Medicine, LLC, a Cerecor companyRan2016 to 2017Enrolled101ConditionsAttention Deficit Disorder With HyperactivityArmsNFC-1, Placebo
NCT02895906 phase1completednot on this map

A 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD)

TypeinterventionalSponsorAevi Genomic Medicine, LLC, a Cerecor companyRan2016 to 2017Enrolled2Conditions22q11.2 Deletion SyndromeArmsNFC-1
NCT03006367 phase1completednot on this map

An Open-label, Single Ascending Dose, Pharmacokinetic and Tolerability Study of NFC-1 in Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder

TypeinterventionalSponsorAevi Genomic Medicine, LLC, a Cerecor companyRan2017 to 2017Enrolled32ConditionsAttention Deficit Disorder With HyperactivityArmsNFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg, NFC-1 800 mg
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Molecular pharmacology of mGluMolecular pharmacology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Phytoconstituents ofACS omega · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Association ofMolecular syndromology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Joseph T GlessnerCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.ORCID 0000-0001-5131-2811
Munir E KhanCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.
Xiao ChangCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.
Yichuan LiuCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.
F George OtienoCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.
Maria LemmaCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.
Isabella SlabyCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.
Heather HainCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.
Frank MentchCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.
Jin LiDepartment of Cell Biology, the Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China.
Charlly KaoCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.
Patrick M A SleimanCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.
Michael E MarchCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.
John ConnollyCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA.
Hakon HakonarsonCenter for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, USA. hakonarson@chop.edu.
Children's Hospital of Philadelphia · USTianjin Medical University · CN

Funding

Utilizing Polygenic Risk to Understand and Improve Outcomes: A Model For Overturning Health Disparities Through Minority-Enriched Genomics HealthcareU01HG011175 · NHGRI · CHILDREN'S HOSP OF PHILADELPHIA · PI Hakon Hakonarson · 2020 to 2026
$10.3M
The Intellectual and Developmental Disabilities Research Center (IDDRC) at CHOP/PennP50HD105354 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI ERIC D MARSH, ROBERT Thomas SCHULTZ · 2021 to 2026
$9.2M
The Intellectual and Developmental Disabilities Research Center at CHOP/PennU54HD086984 · NICHD · CHILDREN'S HOSP OF PHILADELPHIA · PI ROBERTS, TIMOTHY P · 2016 to 2020
$6.3M
Integrative Analysis of a GWAS Repository with EMRs from over 40,000 ChildrenU01HG006830 · NHGRI · CHILDREN'S HOSP OF PHILADELPHIA · PI HAKONARSON, HAKON · 2012 to 2014
$3.7M
NHGRI NIH HHS U01 HG006830NHGRI NIH HHS U01-HG006830NHGRI NIH HHS U01 HG011175NICHD NIH HHS P50 HD105354NICHD NIH HHS U54 HD086984
6 · The paper itself

Abstract

backgroundNeurodevelopmental disorders (NDDs), such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), are examples of complex and partially overlapping phenotypes that often lack definitive corroborating genetic information. ADHD and ASD have complex genetic associations implicated by rare recurrent copy number variations (CNVs). Both of these NDDs have been shown to share similar biological etiologies as well as genetic pleiotropy.

methodsPlatforms aimed at investigating genetic-based associations, such as high-density microarray technologies, have been groundbreaking techniques in the field of complex diseases, aimed at elucidating the underlying disease biology. Previous studies have uncovered CNVs associated with genes within shared candidate genomic networks, including glutamate receptor genes, across multiple different NDDs. To examine shared biological pathways across two of the most common NDDs, we investigated CNVs across 15,689 individuals with ADHD (n = 7920), ASD (n = 4318), or both (n = 3,416), as well as 19,993 controls. Cases and controls were matched by genotype array (i.e., Illumina array versions). Three case-control association studies each calculated and compared the observed vs. expected frequency of CNVs across individual genes, loci, pathways, and gene networks. Quality control measures of confidence in CNV-calling, prior to association analyses, included visual inspection of genotype and hybridization intensity.

resultsHere, we report results from CNV analysis in search for individual genes, loci, pathways, and gene networks. To extend our previous observations implicating a key role of the metabotropic glutamate receptor (mGluR) network in both ADHD and autism, we exhaustively queried patients with ASD and/or ADHD for CNVs associated with the 273 genomic regions of interest within the mGluR gene network (genes with one or two degrees protein-protein interaction with mGluR 1-8 genes). Among CNVs in mGluR network genes, we uncovered CNTN4 deletions enriched in NDD cases (P = 3.22E - 26, OR = 2.49). Additionally, we uncovered PRLHR deletions in 40 ADHD cases and 12 controls (P = 5.26E - 13, OR = 8.45) as well as clinically diagnostic relevant 22q11.2 duplications and 16p11.2 duplications in 23 ADHD + ASD cases and 9 controls (P = 4.08E - 13, OR = 15.05) and 22q11.2 duplications in 34 ADHD + ASD cases and 51 controls (P = 9.21E - 9, OR = 3.93); those control samples were not with previous 22qDS diagnosis in their EHR records.

conclusionTogether, these results suggest that disruption in neuronal cell-adhesion pathways confers significant risk to NDDs and showcase that rare recurrent CNVs in CNTN4, 22q11.2, and 16p11.2 are overrepresented in NDDs that constitute patients predominantly suffering from ADHD and ASD.

trial registrationClinicalTrials.gov Identifier: NCT02286817 First Posted: 10 November 14, ClinicalTrials.gov Identifier: NCT02777931 first posted: 19 May 2016, ClinicalTrials.gov Identifier: NCT03006367 first posted: 30 December 2016, ClinicalTrials.gov Identifier: NCT02895906 first posted: 12 September 2016.

Indexed as

Autism Spectrum DisorderReceptors, Metabotropic GlutamateDNA Copy Number VariationsGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansReceptors, Metabotropic GlutamateAttention-deficit/hyperactivity disorderAutismCopy number variationGenetic association studyMetabotropic glutamate receptorsNeurodevelopmental disorders

Identifiers

PMID37120522
PMCPMC10148449
OpenAlexW4367368611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.